Reinforcing RAF

The theory behind the development of BAY 43-9006, a Raf kinase inhibitor in development by Onyx Pharmaceuticals Inc. and partner Bayer AG, is based on the knowledge that raf kinase is oncogenic in human cancers and is part of the

Read the full 404 word article

How to gain access

Continue reading with a
two-week free trial.